[New therapeutic options in pulmonary diseases in 2016 : focus on asthma, COPD and idiopathic pulmonary fibrosis (IPF)].

Abstract

We chose, for this update on novelties in treatments for pulmonary disorders in 2016, to focus on advances in 3 pulmonary disorders : chronic obstructive pulmonary disease (COPD), asthma and IPF. For COPD, the contribution of inhaled glucocorticosteroids and roflumilast are revisited and the benefits obtained through endoscopic volume reduction procedures are clarified. In asthma and IPF, new molecules offer new hopes : a bettre control of exacerbations in asthma and a stabilisation or slowing of disease progression in IPF.

• Authors: Pietro Gianella, Nicolas Glatz, Gregory Berra, Jean-Paul Janssens
• Journal: Revue medicale suisse (Rev Med Suisse) Vol. 13 Issue 544-545 Pg. 96-101 (Jan 11 2017) ISSN: 1660-9379 [Print] Switzerland
• Vernacular Title: Pneumologie. Données sur l’asthme, la BPCO et la fibrose pulmonaire.
• PMID: 28703547 (Publication Type: Journal Article, Review)

Chemical References

• Aminopyridines
• Benzamides
• Cyclopropanes
• Roflumilast

Topics

• Aminopyridines (therapeutic use)
• Asthma (drug therapy)
• Benzamides (therapeutic use)
• Cyclopropanes (therapeutic use)
• Humans
• Idiopathic Pulmonary Fibrosis (therapy)
• Lung Diseases (therapy)
• Pulmonary Disease, Chronic Obstructive (drug therapy)
• Pulmonary Medicine (methods, trends)
• Therapies, Investigational (methods, trends)